Sally Kay

Cooley advised AN2 Therapeutics on its $79 million initial public offering of 4,600,000 shares of common stock at a price to the public of $15.00 per share. AN2 is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Partner Josh Seidenfeld, associate Anitha Anne and Sally Kay of counsel led the Cooley team.

Cooley advised Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders, on its agreement to sell to Alexion Pharmaceuticals for $18 per share in cash – a value of $1.41 billion. Jamie Leigh, Ian Nussbaum, Kenneth Guernsey, Robert Jones and Sally Kay led the Cooley team advising Portola on the transaction, which is expected to close in Q3. 

Palo Alto, Calif. – Cooley is advising ProteinSimple on its sale to Techne (d/b/a Bio-Techne) for $300 million. ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Techne is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities.

The transaction is subject to the satisfaction of customary closing conditions and will be financed through a combination of cash on hand and a new revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.

Palo Alto, Calif. – Cooley advised Portola Pharmaceuticals on its $140 million initial public offering. Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. It now trades on the Nasdaq Global Stock Market under the symbol "PTLA.